SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 13.10 |
Enterprise Value ($M) | 48.34 |
Book Value ($M) | 1.70 |
Book Value / Share | 0.03 |
Price / Book | 7.70 |
NCAV ($M) | -1.22 |
NCAV / Share | -0.02 |
Price / NCAV | -10.77 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -1.13 |
Return on Assets (ROA) | -0.91 |
Return on Equity (ROE) | -19.95 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 0.80 |
Current Ratio | 0.80 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 2.35 |
Assets | 5.27 |
Liabilities | 3.57 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.58 |
Operating Income | -17.25 |
Net Income | -44.54 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -15.84 |
Cash from Investing | -0.36 |
Cash from Financing | 6.26 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13D/A | Cherington Charles | 32.38 | 1,272.52 | |
13G/A | Halpern John D | 9.99 | ||
13G/A | Singer Nicholas Jason | 4.92 | 327.16 | |
13G/A | Iaf, Llc | 5.22 | 364.36 | |
13G/A | Freebird Partners LP | 9.99 | 387.59 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
14,128 | 175,814 | 8.04 | |
27,253 | 94,628 | 28.80 | |
76,742 | 167,070 | 45.93 | |
55,730 | 194,321 | 28.68 | |
21,621 | 53,577 | 40.36 | |
(click for more detail) |
Similar Companies | |
---|---|
ENVB – Enveric Biosciences, Inc. | EPIX – ESSA Pharma Inc. |
EQ – Equillium, Inc. | ESLA – Estrella Immunopharma, Inc. |
EVOK – Evoke Pharma, Inc. |
Financial data and stock pages provided by
Fintel.io